HC Wainwright Issues Positive Forecast for ADAP Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Analysts at HC Wainwright lifted their Q2 2025 earnings per share estimates for Adaptimmune Therapeutics in a report released on Wednesday, May 14th. HC Wainwright analyst A. He now anticipates that the biotechnology company will post earnings per share of ($0.03) for the quarter, up from their prior estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.03) EPS, FY2027 earnings at ($0.01) EPS and FY2029 earnings at $0.05 EPS.

A number of other research analysts have also recently commented on the company. Barclays decreased their price target on Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating on the stock in a research report on Wednesday. Scotiabank decreased their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st. StockNews.com started coverage on Adaptimmune Therapeutics in a research report on Friday. They issued a “buy” rating on the stock. Guggenheim decreased their target price on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research report on Wednesday, March 26th. Finally, Wells Fargo & Company decreased their target price on Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Adaptimmune Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $1.52.

Adaptimmune Therapeutics Stock Up 5.0%

Shares of NASDAQ ADAP opened at $0.28 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.48. The stock has a market capitalization of $71.48 million, a P/E ratio of -1.26 and a beta of 2.86. The stock’s fifty day moving average is $0.28 and its 200 day moving average is $0.50.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.18). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The company had revenue of $7.29 million during the quarter, compared to the consensus estimate of $6.55 million.

Institutional Trading of Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Two Seas Capital LP bought a new stake in Adaptimmune Therapeutics during the fourth quarter worth $7,992,000. Long Focus Capital Management LLC grew its holdings in Adaptimmune Therapeutics by 54.1% during the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock worth $11,040,000 after buying an additional 7,194,503 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Adaptimmune Therapeutics by 52.5% during the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock worth $1,361,000 after buying an additional 869,949 shares in the last quarter. Jane Street Group LLC grew its holdings in Adaptimmune Therapeutics by 87.7% during the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after buying an additional 152,780 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after buying an additional 94,623 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.